Kathryn Romano - 26 Feb 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Chief Accounting Officer
Signature
/s/ Kathryn Romano
Issuer symbol
KRYS
Transactions as of
26 Feb 2023
Net transactions value
-$168,218
Form type
4
Filing time
28 Feb 2023, 17:43:33 UTC
Previous filing
01 Mar 2022
Next filing
23 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Tax liability $168,218 -2,144 -12% $78.46 15,984 26 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +20,000 $0.000000 20,000 28 Feb 2023 Common Stock 20,000 $81.91 Direct F3
transaction KRYS Performance Stock Units Award $0 +10,000 $0.000000 10,000 28 Feb 2023 Common Stock 10,000 Direct F4, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2023.
F2 The closing price on February 24, 2023 of the Company's common stock on NASDAQ.
F3 The option vests in four equal annual installments beginning on February 28, 2024.
F4 Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement.
F5 The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance metrics set by the Company's Compensation Committee for this award.
F6 If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025).
F7 If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire.